Synaptogenix Inc. announced, in preparation for its next phase of Bryostatin clinical development, the dosing of its first patient in the Company's open-label dose optimization clinical trial. Synaptogenix's therapeutic lead drug to treat Alzheimer's disease (AD), Bryostatin, recently showed a statistically significant improvement in the treatment group that was not observed in the placebo group in two pilot, placebo-controlled Phase 2 trials. (Thompson et al., JAD 2022).

In the current 6-month trial, enrollment is complete and clinical testing is proceeding toward conclusion. The Company expects to announce topline data from its National Institutes of Health ("NIH") - sponsored, Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe AD during the fourth quarter of 2022.